Compared with placebo, zavegepant nasal spray yielded sustained relief of acute pain and function in migraine.

Salvia BioElectronics has reported the first patient implanted with its ultra-thin implant for chronic migraine in The ...

Biohaven's NDA for Troriluzole was accepted by the FDA, potentially leading to approval in Q3 2025. Click here to find out ...

Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment. Troriluzole demonstrated a 50-70% slowing of SCA disease progression ...

Biohaven (BHVN) announced that the FDA has accepted for review the company’s New Drug Application, or NDA, for troriluzole for the treatment of ...

However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...

Pfizer reported strong 2024 profits Wednesday on the same day the Connecticut Attorney General’s office released a statement saying his office and 37 other states, including Puerto Rico, had settled ...

FDA Approves Symbravo for Acute Treatment of Migraine in Adults By Lori Solomon HealthDay Reporter WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved ...

SG Americas Securities LLC cut its position in Biohaven Ltd. (NYSE ... that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate ...

Without a proper diagnosis, medications that can help reduce migraine may be delayed. Unfortunately, our study found racial and ethnic disparities in the diagnosis, testing and treatment of migraine." ...

Pharma giant Pfizer has agreed to pay $59 million to settle a federal lawsuit accusing a local biopharmaceutical company of paying “kickbacks” to healthcare providers to induce them to prescribe its ...